Physician profile
Ryan Obarzanek
NPI 1346739596
$3,141.10
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $156 · 2021: $294 · 2022: $706 · 2023: $901 · 2024: $840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,741.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,741.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,211.20 | 2021-2024 | Airsupra, Breztri, Andexxa |
| Glaxosmithkline, LLC. | $918.60 | 2019-2024 | Arexvy, Nucala |
| Inari Medical, INC. | $303.92 | 2022-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Genentech USA, INC. | $156.25 | 2020 | |
| Gilead Sciences, INC. | $154.63 | 2022-2024 | Veklury |
| Daiichi Sankyo INC. | $124.55 | 2023 | Injectafer |
| Mallinckrodt Hospital Products INC. | $48.79 | 2024 | Acthar |
| Edwards Lifesciences Corporation | $48.28 | 2022-2024 | Hemosphere |
| Grifols USA, LLC | $43.83 | 2023 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $32.23 | 2022 | |
| Harmony Biosciences LLC | $27.49 | 2022 | |
| Pulmonx Corporation | $22.81 | 2021 | |
| Merck Sharp & Dohme LLC | $20.76 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $15.21 | 2021 | |
| Jazz Pharmaceuticals INC. | $12.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Obarzanek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.